Suboxone Versus Methadone for the Treatment of Opioid Dependence

**Context**
Opioid dependence is related to the misuse of both illegal opioids, such as heroin, and prescription opioids, such as codeine-containing Tylenol, oxycodone, and morphine. Treatment of dependence involves stabilization, detoxification, and maintenance. During detoxification, methadone or buprenorphine are provided as a substitute for misused opioids until the patient is no longer dependent.

**Technology**
Methadone is a long-acting opioid agonist. It is available as a powder, which is dissolved in a liquid for the patient to drink, or as a premixed solution (1 mg/mL). Methadone (10 mg/mL) is a commercial methadone solution, prepared at 10 times the concentration of standard methadone. Suboxone is a fixed-dose combination of buprenorphine (partial agonist at the mu-opioid receptor) and naloxone (opioid antagonist). It is delivered as a tablet slipped under the tongue. Taken orally, buprenorphine alone is absorbed into the bloodstream. However, if Suboxone is crushed and injected, naloxone will enter the bloodstream and cause abrupt withdrawal symptoms (vomiting, diarrhea, muscle cramps).

**Issue**
Suboxone is typically reserved for patients for whom methadone is contraindicated. An updated review of the clinical evidence, including non-randomized controlled trials (RCTs) and cost-effectiveness data, will help to inform decisions about the use of Suboxone for patients with opioid dependence.

**Methods**
A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined selection criteria.

**Key Messages**
- Suboxone had as similar an effect as methadone, with:
  - patients staying on treatment
  - patients not using opioids while on treatment
  - cognitive performance
  - adverse events.
- Suboxone showed a similar cost-effectiveness to methadone in Australia and was more cost-effective than methadone in Greece.
- The risks and benefits of Suboxone for treating special populations such as pregnant women or children are not known.

**Results**
The literature search identified 121 citations, with no additional articles identified from other sources. After screening the abstracts, 28 studies were deemed potentially relevant, with 8 unique clinical studies meeting the criteria for inclusion in this review: 4 RCTs, 2 non-RCTs, and 2 economic evaluations.

**DISCLAIMER:** The information in this Report in Brief is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this Report in Brief should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the Report in Brief to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this Report in Brief.

CADTH takes sole responsibility for the final form and content of this Report in Brief. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government. Production of this Report in Brief is made possible through a financial contribution from Health Canada.